Guideline | Country | Year | Antibiotics | Indications | Immunoglobulins | Indications |
China (MoH)54 | China | 2003 | R | Secondary bacterial infections. | NS | – |
Dermatology Advisor47 | Global | 2017 | NS | – | VIG | Consider in severe infection. |
DermNet48 | Global | 2014 | NS | – | NS | – |
ECDC56 | Europe | 2019 | NS | – | NS | – |
eMedicine49 | Global | 2020 | NS | – | NS | Notes that VIG has not shown efficacy for treatment. |
Ireland HPSC53 | Ireland | 2021 | NS | – | NS | – |
Medscape51 | Global | 2019 | NS | – | NS | Notes that VIG has not shown efficacy in treatment. |
NCDC44 | Nigeria | 2019 | R | Secondary bacterial infections cefuroxime 500 mg two times, 5 days (oral/parental) or ceftriaxone intravenous 1 g, 5 days or B-lactam antibiotics (amoxyl/clavulanic acid, 625 mg ×2/day, ≥5 days. | NS | – |
PHE/UKHSA52 | England | 2019 | NS | – | NS | – |
Singapore FETP46 | Singapore | 2020 | NS | – | NS | – |
Taiwan CDC45 | Taiwan | 2009 | NS | – | NS | – |
UpToDate50 | Global | 2021 | NS | – | NS | – |
US CDC55 | USA | 2018 | NS | – | VIG | Can be considered in severe cases. |
WHO18 | Global | 2019 | NS | – | NS | – |
CDC, Centers for Disease Control; ECDC, European Centre for Disease Control and Prevention; FETP, Singapore Field Epidemiology Training Programme; HPSC, Health Protection Surveillance Centre; MoH, Ministry of Health; NA, not applicable; NCDC, Nigeria Centre for Disease Control; PHE, Public Health England; UKHSA, UK Health Security Agency; VIG, vaccinia immune globulin.